ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Option Therapeutics's annualized return on capital (ROC %) for the quarter that ended in Dec. 2025 was -66.26%.
As of today (2026-06-24), Option Therapeutics's WACC % is 0.00%. Option Therapeutics's ROC % is 0.00% (calculated using TTM income statement data).
Option Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Option Therapeutics (AMEX:OPTN) ROC % Explanation
ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.
There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.
Why is ROC % important?
Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Option Therapeutics's WACC % is 0.00%. Option Therapeutics's ROC % is 0.00% (calculated using TTM income statement data).
Option Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.
Be Aware
Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Option Therapeutics ROC % Related Terms
Option Therapeutics ROC % Historical Data
* Premium members only.
The historical data trend for Option Therapeutics's ROC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note:
The Operating Income data used here is four times the quarterly (Dec. 2025) data.
The tax rate is limited to between 0% and 100%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Option Therapeutics (OPTN) has a ROC % of -66.26% as of Dec. 2025. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Option Therapeutics and its competitors.
Is Option Therapeutics' ROC % too high?
Option Therapeutics' current ROC % is -66.26%.
How does Option Therapeutics' ROC % compare to ?
Option Therapeutics' ROC % of -66.26% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Option Therapeutics and its competitors. Option Therapeutics's current ROC % is -66.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Option Therapeutics stock overvalued right now?
Option Therapeutics (OPTN) has a current ROC % of -66.26%. The current ROC % is -66.26%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Option Therapeutics (OPTN), the current ROC % is -66.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address680 West Nye Lane, Suite 201, Carson, NV, USA, 89703
Option Therapeutics Inc is a clinical-stage company developing inventive drug therapies to treat debilitating and life-threatening liver disease through its investigational drug candidate BIV201 (continuous infusion terlipressin). BIV201 is administered as a patent-pending liquid formulation of terlipressin with patents issued, to date, in the U.S., China, Japan, Chile, and India.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPTN has been successfully added to your